Evidence map›Paper›PMID 39820598›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Value of [

Yafei Zhang, Mimi Xu, Yu Wang, Fang Yu, Xinxin Chen, Guangfa Wang, Kui Zhao, Hong Yang, Xinhui Su

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  3. European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yafei Zhang *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Mimi Xu *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Yu WangDepartment of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China.
Fang YuDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Xinxin ChenDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Guangfa WangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Kui ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Hong YangDepartment of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China. 1307017@zju.edu.cn.
Xinhui SuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China. suxinhui@zju.edu.cn.ORCID 0000-0002-4782-3982

Funding

Major plan of Jointly Constructed project by the Science and Technology Department of the State Administration of Traditional Chinese Medicine and the Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-24025National Key Research and Development Program of China 2023YFF0716000National Natural Science Foundation of China 82071965National Natural Science Foundation of China 82472013Science and Technology Plan Program of Traditional Chinese Medicine of Zhejiang Province 2024ZR093
6 · The paper itself

Abstract

objectivesThis study aimed to evaluate the predictive value of [

methodsThis study included 34 patients with histopathologically and radiologically confirmed LAPDAC who received [

resultsOf 34 patients with LAPDAC, 14 patients had a pathologic good response (PGR, Evans III-IV), and 20 patients had a pathologic poor response (PPR, Evans I-II). Both the primary tumor SUV

conclusionsThe parameters of [

Indexed as

Carcinoma, Pancreatic DuctalHeterocyclic Compounds, 1-RingNeoadjuvant TherapyPancreatic NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsSurvival AnalysisTreatment OutcomeHeterocyclic Compounds, 1-RingRadiopharmaceuticals[18F]AlF-NOTA-FAPI-04Neoadjuvant chemotherapyPancreatic ductal adenocarcinomaPathological response

Identifiers

PMID39820598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.